These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
95 related articles for article (PubMed ID: 20530291)
1. Pharmacological therapy for hypertensive children: an "additional bypass" of lifestyle interventions. Thomopoulos C; Tsioufis C; Makris T; Stefanadis C Hypertension; 2010 Aug; 56(2):e19; author reply e20. PubMed ID: 20530291 [No Abstract] [Full Text] [Related]
2. Safety and efficacy of olmesartan: an observational pooled-analysis of 156,682 hypertensive patients. Scholze J; Schaefer A; Kreutz R Expert Opin Drug Saf; 2011 Mar; 10(2):185-96. PubMed ID: 21254872 [TBL] [Abstract][Full Text] [Related]
3. Two amlodipine/ARB combinations for hypertension. Med Lett Drugs Ther; 2007 Dec; 49(1276):101-2. PubMed ID: 18084152 [No Abstract] [Full Text] [Related]
4. [Not just blood pressure counts. How well are hypertensive patients controlled?]. MMW Fortschr Med; 2003 Sep; 145(38):64. PubMed ID: 14603692 [No Abstract] [Full Text] [Related]
5. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160). Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280 [TBL] [Abstract][Full Text] [Related]
6. [In diarrhea of unknown origin also think of olmesartan!]. Storr M MMW Fortschr Med; 2015 Mar; 157(4):34. PubMed ID: 25743974 [No Abstract] [Full Text] [Related]
7. [Fast and strong lowering of pressure. The newest sartan has passed the practice test]. MMW Fortschr Med; 2003 Oct; 145(44):45. PubMed ID: 14655509 [No Abstract] [Full Text] [Related]
8. Rationale, study design and implementation of the COLM study: the combination of OLMesartan and calcium channel blocker or diuretic in high-risk elderly hypertensive patients. Ogihara T; Saruta T; Rakugi H; Shimamoto K; Ito S; Matsuoka H; Horiuchi M; Imaizumi T; Takishita S; Higaki J; Katayama S; Saito I; Shimada K; Hypertens Res; 2009 Feb; 32(2):163-7. PubMed ID: 19262477 [TBL] [Abstract][Full Text] [Related]
9. Combination therapy for hypertension: focus on high-dose olmesartan medoxomil (40 mg) plus hydrochlorothiazide. Rump LC; Sellin L Expert Opin Pharmacother; 2010 Sep; 11(13):2231-42. PubMed ID: 20707758 [TBL] [Abstract][Full Text] [Related]
11. [Therapy of hypertension. A new rapidly effective AT1 blocker]. MMW Fortschr Med; 2002 Jun; 144(25):55. PubMed ID: 12136675 [No Abstract] [Full Text] [Related]
12. Why COLM and ACCOMPLISH study results differ. Cífková R J Hypertens; 2014 Oct; 32(10):1967-9. PubMed ID: 25186528 [No Abstract] [Full Text] [Related]
13. A new class of antihypertensive: angiotensin II receptor antagonists. McCoy R S D J Med; 1995 Sep; 48(9):319-20. PubMed ID: 7481726 [No Abstract] [Full Text] [Related]
14. Antihypertensive efficacy and safety of olmesartan and ramipril in elderly patients with mild to moderate systolic and diastolic essential hypertension. Mallion JM; Omboni S; Barton J; Van Mieghem W; Narkiewicz K; Panzer PK; Puig JG; Stefanadis C; Zweiker R; Blood Press Suppl; 2011 Apr; 1():3-11. PubMed ID: 21091270 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of an amlodipine/olmesartan treatment algorithm in patients with or without type 2 diabetes and hypertension (a secondary analysis of the BP-CRUSH study). Nesbitt SD; Shojaee A; Maa JF; Weir MR J Hum Hypertens; 2013 Jul; 27(7):445-52. PubMed ID: 23254596 [TBL] [Abstract][Full Text] [Related]
16. [Medication of the month. Olmesartan medoxomil hydroclorothiazide (Olmetec Plus or Belsar Plus]. Lancellotti P Rev Med Liege; 2007 Mar; 62(3):175-9. PubMed ID: 17511387 [TBL] [Abstract][Full Text] [Related]
17. [Sprue-like enteropathy due to olmesartan: a case report]. Agudo Fernández S Gastroenterol Hepatol; 2015 Feb; 38(2):108-9. PubMed ID: 24958550 [No Abstract] [Full Text] [Related]
18. Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker. Furuhashi M; Moniwa N; Mita T; Fuseya T; Ishimura S; Ohno K; Shibata S; Tanaka M; Watanabe Y; Akasaka H; Ohnishi H; Yoshida H; Takizawa H; Saitoh S; Ura N; Shimamoto K; Miura T Am J Hypertens; 2015 Jan; 28(1):15-21. PubMed ID: 24842388 [TBL] [Abstract][Full Text] [Related]
19. Olmesartan medoxomil: recent clinical and experimental acquisitions. Destro M; Preti P; D'Ospina A; Christian Achiri NN; Ricci AR; Cagnoni F Expert Opin Drug Metab Toxicol; 2009 Sep; 5(9):1149-57. PubMed ID: 19689219 [TBL] [Abstract][Full Text] [Related]